Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287033 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
A Phase 1 study of Peanut Allergies, sponsored by Mabylon.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT07287033 is a Phase 1 study of Peanut Allergies that is actively recruiting participants, run by Mabylon. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07287033, a Phase 1 study of Peanut Allergies, is actively recruiting participants, sponsored by Mabylon.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged acceptable, the second part of the study will be started. In the second part of the study, adult and adolescent participants with peanut allergy receive one dose of MY006 or a placebo, administered by subcutaneous injection. Several weeks later, the participants are given a food peanut challenge to assess reactions and treatment effects. The duration of the study for participants is for up to 32 weeks.
Conditions Studied
Interventions
- DRUG MY006 Low Dose
- DRUG MY006 Mid Dose
- DRUG MY006 High Dose
- DRUG MY006 Selected Dose
- DRUG Placebo (Vehicle)
Study Locations (1)
Florida
- Syneos Health Clinical Research Services LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-12-06 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07287033
The ClinicalTrials.gov registry entry for NCT07287033 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mabylon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergies appearing as the primary indexed condition, and to 5 interventions - of which MY006 Low Dose is the first listed.
NCT07287033 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07287033 about?
NCT07287033 is a clinical study titled "Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy". The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or ...
What is the current status of trial NCT07287033?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-12-06. Estimated completion is 2027-04.
What conditions does trial NCT07287033 study?
This clinical trial studies the following conditions: Peanut Allergies.
What interventions are being tested in trial NCT07287033?
The interventions under investigation include: MY006 Low Dose (DRUG), MY006 Mid Dose (DRUG), MY006 High Dose (DRUG), MY006 Selected Dose (DRUG), Placebo (Vehicle) (DRUG).
Who is sponsoring clinical trial NCT07287033?
This trial is sponsored by Mabylon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287033 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.